Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin/Tazobactam vs Carbapenems in ESBL UTI
NCT03891433Phase 4Suspended
- Sponsor
- Universidad del Norte
- Start
- Apr 2019
- Primary completion
- Dec 2024
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of piperacillin + tazobactam in urinary tract infection (UTI) (2 arms), sponsored by Universidad del Norte. Primary endpoint: Clinical cure. Started Apr 2019; status: suspended.
02
Drugs
piperacillin + tazobactam
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT03891433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891433.